1 Wild CP, W. E., Stewart BW, editors World Cancer Report: Cancer Research for Cancer Prevention. (2020).
2 Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399-404, doi:10.1038/s41586-019-1007-8 (2019).
3 Pan, H. et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 377, 1836-1846, doi:10.1056/NEJMoa1701830 (2017).
4 Turajlic, S. et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell 173, 581-594 e512, doi:10.1016/j.cell.2018.03.057 (2018).
5 DerHagopian, R. P., Sugarbaker, E. V. & Ketcham, A. Inflammatory oncotaxis. JAMA 240, 374-375 (1978).
6 Ewing, J. The Modern Attitude Toward Traumatic Cancer. Bull N Y Acad Med 11, 281-333 (1935).
7 Jones, F. S. & Rous, P. On the Cause of the Localization of Secondary Tumors at Points of Injury. J Exp Med 20, 404-412, doi:10.1084/jem.20.4.404 (1914).
8 Smith, H. A. & Kang, Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91, 411-429, doi:10.1007/s00109-013-1021-5 (2013).
9 Rybinski, B., Franco-Barraza, J. & Cukierman, E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics 46, 223-244, doi:10.1152/physiolgenomics.00158.2013 (2014).
10 Abbas, S., Ihle, P., Koster, I. & Schubert, I. Estimation of disease incidence in claims data dependent on the length of follow-up: a methodological approach. Health Serv Res 47, 746-755, doi:10.1111/j.1475-6773.2011.01325.x (2012).
11 Eastell, R. et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 22, 857-862, doi:10.1093/annonc/mdq541 (2011).
12 Heeke, A., Nunes, M. R. & Lynce, F. Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. Curr Breast Cancer Rep 10, 241-250, doi:10.1007/s12609-018-0295-6 (2018).
13 Braun, S. et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342, 525-533, doi:10.1056/NEJM200002243420801 (2000).
14 Braun, S. et al. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 19, 368-375, doi:10.1200/JCO.2001.19.2.368 (2001).
15 Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353, 793-802, doi:10.1056/NEJMoa050434 (2005).
16 Werner, S. & Pantel, K. Tracing the Seeds in the Soil. Clin Chem 63, 1764-1765, doi:10.1373/clinchem.2017.274290 (2017).
17 Riethdorf, S. et al. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res 23, 5384-5393, doi:10.1158/1078-0432.CCR-17-0255 (2017).
18 Kang, Y. & Pantel, K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23, 573-581, doi:10.1016/j.ccr.2013.04.017 (2013).
19 Pantel, K. & Hayes, D. F. Disseminated breast tumour cells: biological and clinical meaning. Nat Rev Clin Oncol 15, 129-131, doi:10.1038/nrclinonc.2017.174 (2018).
20 Celia-Terrassa, T. & Kang, Y. Metastatic niche functions and therapeutic opportunities. Nat Cell Biol 20, 868-877, doi:10.1038/s41556-018-0145-9 (2018).
21 Bahney, C. S. et al. Cellular biology of fracture healing. J Orthop Res 37, 35-50, doi:10.1002/jor.24170 (2019).
22 Cassetta, L. et al. Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell 35, 588-602 e510, doi:10.1016/j.ccell.2019.02.009 (2019).
23 Mohme, M., Riethdorf, S. & Pantel, K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol 14, 155-167, doi:10.1038/nrclinonc.2016.144 (2017).
24 Bardia, A. et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99, 881-889, doi:10.1093/jnci/djk200 (2007).
25 Huang, X. Z. et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control 26, 589-600, doi:10.1007/s10552-015-0539-y (2015).
26 Schafer, I. et al. Multimorbidity patterns and 5-year overall mortality: Results from a claims data-based observational study. J Comorb 8, 2235042X18816588, doi:10.1177/2235042X18816588 (2018).
27 Hlatky, M. A. et al. Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes 7, 157-162, doi:10.1161/CIRCOUTCOMES.113.000373 (2014).
28 Heller, G., Gunster, C., Misselwitz, B., Feller, A. & Schmidt, S. [Annual patient volume and survival of very low birth weight infants (VLBWs) in Germany--a nationwide analysis based on administrative data]. Z Geburtshilfe Neonatol 211, 123-131, doi:10.1055/s-2007-960747 (2007).
29 Lowenstern, A. et al. Use of Medicare Claims to Identify Adverse Clinical Outcomes After Mitral Valve Repair. Circ Cardiovasc Interv 12, e007451, doi:10.1161/CIRCINTERVENTIONS.118.007451 (2019).